Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breakthrough's Achilles Heel: Alexion’s Newly Acquired Kanuma Delayed By Manufacturing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA extends the PDUFA date for enzyme replacement therapy by three months so agency can review chemistry, manufacturing and controls information; another drug, Strensiq, is also pending at FDA without any action.

You may also be interested in...



Alexion Gets Second Priority Review Voucher With Approval Of Rare Enzyme Disorder Drug

Kanuma, the first approved treatment for lysosomal acid lipase deficiency, will launch in January at an average annual treatment cost of $310,000.

Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval

Alexion plans to use voucher for one of its own products and might be targeting its next-generation version of blockbuster Soliris.

Keeping Track: Four Novel Agents Clear FDA; Two Complete Response Letters Issued

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel